Product Information
VERAPAMIL ER PM 300 MG CAPSULE is a generic product labeled by Wilshire Pharmaceuticals Inc., priced at $7.9202 per EA under NDC 52536048737. Its NADAC has been published 52 times since Oct 8, 2025.
FDA first approved this application on Nov 25, 1998.
Strength
300 mg/1
Manufacturer
Wilshire Pharmaceuticals Inc.NDC
52536048737
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VERAPAMIL HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA020943FDA Approved
11/25/1998
On Market Since
11/26/2024
Pharmacological Classes
Price Statistics
The NADAC for VERAPAMIL ER PM 300 MG CAPSULE has been published 52 times since Oct 8, 2025, and over the history we have for it it has risen 4.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.9202 per EA |
|---|---|
| All-time high | $8.0429 (May 13, 2026) |
| All-time low | $7.5962 (Oct 8, 2025) |
| 52-week high | $8.0429 |
| 52-week low | $7.5962 |
| Median price | $7.9109 |
| Average price | $7.8445 |
| Largest weekly change | +2.3% (Feb 18, 2026) |
| Weeks tracked | 52 |
| Tracking since | Oct 8, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Wilshire Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Verapamil Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VERAPAMIL ER PM 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for VERAPAMIL ER PM 300 MG CAPSULE, manufactured by Wilshire Pharmaceuticals Inc., is $7.9202 per EA (NDC 52536048737), effective Sep 30, 2026.
How has the price of VERAPAMIL ER PM 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for VERAPAMIL ER PM 300 MG CAPSULE has risen 4.3%. It has been tracked across 52 weekly CMS publications since Oct 8, 2025.
What are the highest and lowest recorded NADAC prices for VERAPAMIL ER PM 300 MG CAPSULE?
Since Oct 8, 2025, the NADAC for VERAPAMIL ER PM 300 MG CAPSULE has ranged from a low of $7.5962 (Oct 8, 2025) to a high of $8.0429 (May 13, 2026), with a median of $7.9109 per EA.
Are there cheaper alternatives to VERAPAMIL ER PM 300 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as VERAPAMIL ER PM 300 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures VERAPAMIL ER PM 300 MG CAPSULE?
VERAPAMIL ER PM 300 MG CAPSULE (NDC 52536048737) is labeled by Wilshire Pharmaceuticals Inc., and CMS classifies it as a generic product.